Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_13-cv-03248/USCOURTS-cand-3_13-cv-03248-27/pdf.json

Nature of Suit Code: 850
Nature of Suit: Securities, Commodities, Exchange
Cause of Action: 15:78m(a) Securities Exchange Act

---

United States District Court

For the Northern District of California

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF CALIFORNIA

BIOTECHNOLOGY VALUE FUND, L.P.,

BIOTECHNOLOGY VALUE FUND II,

L.P., INVESTMENT 10, L.L.C., BVF

INVESTMENTS, L.L.C.; BVF INC., and

BVF X, LLC,

Plaintiffs,

v.

CELERA CORPORATION, CREDIT

SUISSE SECURITIES (USA) LLC,

KATHY ORDOÑEZ, RICHARD H.

AYERS, WILLIAM G. GREEN, PETER

BARTON HUTT, GAIL M. NAUGHTON,

WAYNE I. ROE, and BENNETT M.

SHAPIRO,

Defendants. /

No. C 13-03248 WHA

REQUEST FOR ADDITIONAL

BRIEFING

Both parties are requested to respond to the following questions in FIVE PAGES OR LESS

BY 6:00 A.M. ON JANUARY 13, 2015.

Does the summary judgment record show the percentage of shareholders who voted for

the sale? Was a simple majority all that was required? 

Did plaintiffs vote against the sale? Does the summary judgment record show this?

What difference should appraisal rights make? 

What is plaintiffs’ proof in the summary judgment record that had the corrected

information been revealed, a sufficient number of yes-vote stockholders would have changed

their votes to no to defeat the deal?

Dated: January 12, 2015. WILLIAM ALSUP

UNITED STATES DISTRICT JUDGE

Case 3:13-cv-03248-WHA Document 264 Filed 01/12/15 Page 1 of 1